JP2014509297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509297A5 JP2014509297A5 JP2013532866A JP2013532866A JP2014509297A5 JP 2014509297 A5 JP2014509297 A5 JP 2014509297A5 JP 2013532866 A JP2013532866 A JP 2013532866A JP 2013532866 A JP2013532866 A JP 2013532866A JP 2014509297 A5 JP2014509297 A5 JP 2014509297A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- alkoxy
- optionally substituted
- alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003545 alkoxy group Chemical group 0.000 claims 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 28
- 150000002367 halogens Chemical group 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 238000000034 method Methods 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 12
- 229920002554 vinyl polymer Polymers 0.000 claims 12
- -1 heteroaliphatic Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000002431 hydrogen Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 125000002723 alicyclic group Chemical group 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- SCDNPHPQYKUMQW-AATRIKPKSA-N 2-[(E)-2-(1H-pyrazol-5-yl)ethenyl]-1H-indole Chemical compound C=1C2=CC=CC=C2NC=1\C=C\C=1C=CNN=1 SCDNPHPQYKUMQW-AATRIKPKSA-N 0.000 claims 1
- SCDNPHPQYKUMQW-WAYWQWQTSA-N 2-[(Z)-2-(1H-pyrazol-5-yl)ethenyl]-1H-indole Chemical compound C=1C2=CC=CC=C2NC=1/C=C\C=1C=CNN=1 SCDNPHPQYKUMQW-WAYWQWQTSA-N 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- RYTGQEUHMMXXMN-ONEGZZNKSA-N 5-[(E)-2-(1H-pyrrol-2-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNN=C1/C=C/C1=CC=CN1 RYTGQEUHMMXXMN-ONEGZZNKSA-N 0.000 claims 1
- QNQPCKJLSXTOPS-OWOJBTEDSA-N 5-[(E)-2-(1H-pyrrol-3-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNC=C1/C=C/C=1C=CNN=1 QNQPCKJLSXTOPS-OWOJBTEDSA-N 0.000 claims 1
- RYTGQEUHMMXXMN-ARJAWSKDSA-N 5-[(Z)-2-(1H-pyrrol-2-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNN=C1/C=C\C1=CC=CN1 RYTGQEUHMMXXMN-ARJAWSKDSA-N 0.000 claims 1
- QNQPCKJLSXTOPS-UPHRSURJSA-N 5-[(Z)-2-(1H-pyrrol-3-yl)ethenyl]-1H-pyrazole Chemical compound C1=CNC=C1/C=C\C=1C=CNN=1 QNQPCKJLSXTOPS-UPHRSURJSA-N 0.000 claims 1
- WTLCERBYPIMJNW-SNAWJCMRSA-N 5-[(e)-2-(2,6-dichlorophenyl)ethenyl]-1h-pyrazole Chemical compound ClC1=CC=CC(Cl)=C1\C=C\C1=CC=NN1 WTLCERBYPIMJNW-SNAWJCMRSA-N 0.000 claims 1
- FSONDHSXOHJMCO-GORDUTHDSA-N 5-[(e)-2-(4-methoxyphenyl)ethenyl]-1h-pyrazole Chemical compound C1=CC(OC)=CC=C1\C=C\C1=NNC=C1 FSONDHSXOHJMCO-GORDUTHDSA-N 0.000 claims 1
- YKUVDPWPDNKMPQ-OWOJBTEDSA-N 5-[(e)-2-(5-nitrofuran-2-yl)ethenyl]-1h-pyrazole Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C1=NNC=C1 YKUVDPWPDNKMPQ-OWOJBTEDSA-N 0.000 claims 1
- JJZCXCVBDQAHLT-OWOJBTEDSA-N 5-[(e)-2-(furan-3-yl)ethenyl]-1h-pyrazole Chemical compound C1=COC=C1/C=C/C=1C=CNN=1 JJZCXCVBDQAHLT-OWOJBTEDSA-N 0.000 claims 1
- NFLQSIIRRGMWIY-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]-1h-pyrazole Chemical compound C1=CNN=C1/C=C/C1=CC=CC=C1 NFLQSIIRRGMWIY-VOTSOKGWSA-N 0.000 claims 1
- SVGZNMNPBUUXQL-OWOJBTEDSA-N 5-[(e)-2-thiophen-3-ylethenyl]-1h-pyrazole Chemical compound C1=CSC=C1/C=C/C=1C=CNN=1 SVGZNMNPBUUXQL-OWOJBTEDSA-N 0.000 claims 1
- WTLCERBYPIMJNW-PLNGDYQASA-N 5-[(z)-2-(2,6-dichlorophenyl)ethenyl]-1h-pyrazole Chemical compound ClC1=CC=CC(Cl)=C1\C=C/C1=NNC=C1 WTLCERBYPIMJNW-PLNGDYQASA-N 0.000 claims 1
- FSONDHSXOHJMCO-DJWKRKHSSA-N 5-[(z)-2-(4-methoxyphenyl)ethenyl]-1h-pyrazole Chemical compound C1=CC(OC)=CC=C1\C=C/C1=NNC=C1 FSONDHSXOHJMCO-DJWKRKHSSA-N 0.000 claims 1
- YKUVDPWPDNKMPQ-UPHRSURJSA-N 5-[(z)-2-(5-nitrofuran-2-yl)ethenyl]-1h-pyrazole Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C/C1=NNC=C1 YKUVDPWPDNKMPQ-UPHRSURJSA-N 0.000 claims 1
- HYJHSSBFLWWIIS-VURMDHGXSA-N 5-[(z)-2-naphthalen-2-ylethenyl]-1h-pyrazole Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C\C=1C=CNN=1 HYJHSSBFLWWIIS-VURMDHGXSA-N 0.000 claims 1
- NFLQSIIRRGMWIY-SREVYHEPSA-N 5-[(z)-2-phenylethenyl]-1h-pyrazole Chemical compound C1=CNN=C1/C=C\C1=CC=CC=C1 NFLQSIIRRGMWIY-SREVYHEPSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40454510P | 2010-10-05 | 2010-10-05 | |
| US61/404,545 | 2010-10-05 | ||
| US45536210P | 2010-10-19 | 2010-10-19 | |
| US61/455,362 | 2010-10-19 | ||
| PCT/US2011/054670 WO2012047826A2 (en) | 2010-10-05 | 2011-10-04 | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509297A JP2014509297A (ja) | 2014-04-17 |
| JP2014509297A5 true JP2014509297A5 (https=) | 2014-10-30 |
Family
ID=45928362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532866A Pending JP2014509297A (ja) | 2010-10-05 | 2011-10-04 | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130190376A1 (https=) |
| EP (1) | EP2624830A4 (https=) |
| JP (1) | JP2014509297A (https=) |
| AU (1) | AU2011312333A1 (https=) |
| CA (1) | CA2813719A1 (https=) |
| IL (1) | IL225494A0 (https=) |
| WO (1) | WO2012047826A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102149379A (zh) | 2008-07-10 | 2011-08-10 | 安吉翁生物医药有限公司 | 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物 |
| EP3927702A4 (en) * | 2019-04-11 | 2022-05-11 | Angion Biomedica Corp. | SOLID FORMS OF (E)-3-[2-(2-THIENYL)VINYL]-1H-PYRAZOLE |
| US20230000828A1 (en) * | 2019-10-31 | 2023-01-05 | Angion Biomedica Corp. | Improving renal function after kidney transplantation |
| EP4228626A2 (en) * | 2020-10-14 | 2023-08-23 | Angion Biomedica Corp. | Preparation of terevalefim and formulations thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| AU2001277854B2 (en) * | 2000-06-29 | 2007-03-01 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| US6610726B2 (en) * | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8193177B2 (en) * | 2007-11-13 | 2012-06-05 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases |
| CN102149379A (zh) * | 2008-07-10 | 2011-08-10 | 安吉翁生物医药有限公司 | 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物 |
-
2011
- 2011-10-04 JP JP2013532866A patent/JP2014509297A/ja active Pending
- 2011-10-04 WO PCT/US2011/054670 patent/WO2012047826A2/en not_active Ceased
- 2011-10-04 CA CA2813719A patent/CA2813719A1/en not_active Abandoned
- 2011-10-04 EP EP11831414.5A patent/EP2624830A4/en not_active Withdrawn
- 2011-10-04 US US13/877,453 patent/US20130190376A1/en not_active Abandoned
- 2011-10-04 AU AU2011312333A patent/AU2011312333A1/en not_active Abandoned
-
2013
- 2013-04-02 IL IL225494A patent/IL225494A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (https=) | ||
| JP5040656B2 (ja) | トリアリールカルボン酸誘導体 | |
| JP2019094345A5 (https=) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2011527675A5 (https=) | ||
| JP2019519598A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2013532652A5 (https=) | ||
| JP2014530900A5 (https=) | ||
| JP2019522055A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| JP2006513221A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2011526917A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2007524696A5 (https=) | ||
| JP2018529745A5 (https=) | ||
| JP2009500347A5 (https=) | ||
| JP2013544860A5 (https=) | ||
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| JP2020535165A5 (https=) | ||
| JP2014509297A5 (https=) | ||
| RU2014107000A (ru) | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств |